PT  - JOURNAL ARTICLE
AU  - Carlos Maximiliano Dutra
TI  - Non-Linear Fitting of Sigmoidal Growth Curves to predict a maximum limit to the total number of COVID-19 cases in the United States
AID  - 10.1101/2020.04.22.20074898
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.22.20074898
4099  - http://medrxiv.org/content/early/2020/04/25/2020.04.22.20074898.short
4100  - http://medrxiv.org/content/early/2020/04/25/2020.04.22.20074898.full
AB  - In the present work is used non-linear fitting of the “Gompert” and “Logistic” growth models to the number of total COVID-19 cases from the United States as a country and individually by states. The methodology allowed us to estimate that the maximum limit for the total number of cases of COVID-19 patients such as those registered with the World Health Organization will be approximately one million and one hundred thousand cases to the United States. Up to 04/19/20 the models indicate that United States reached 70% of this maximum number of “total cases” and the United States will reach 95% of this limit by 05/14/2020. The application of the nonlinear fitting of growth curves to the individual data of each American state showed that only 25% of them did not reach, on 04/19/20, the percentage of 59% of the maximum limit of “total cases” and that 17 of the 50 states still will not have reached 95% of that limit on 05/14/20.Competing Interest StatementThe authors have declared no competing interest.Funding Statementwithout fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are all available.